Charles River Laboratories International, Inc.

CRL Healthcare Diagnostics & Research

Charles River Laboratories International, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, down 0.85% from fiscal 2024.

Revenue
−2.20%
EPS
+530.3%
Free cash flow
+16.3%
Total debt
+11.8%

Quarter to September 2026, against a year earlier

313.98 12.31 −3.77%
Market cap
$14.9B
P/E
300×
Fwd P/E
89.2×
Dividend yield
—
F-score
5/9
Altman Z
2.40
Beneish M
−3.11
Dividend safety
n/a
Sep '26 Jun '26 Mar '26 Dec '25 Older periods
P/E ratio
281.96 0.00 0.00 0.00

+8 more quarters

P/S ratio
3.55 2.72 2.10 2.46
P/FCF ratio
35.29 29.39 21.58 19.07
P/Operating CF
55.50 60.60 205.57 67.02
P/B ratio
4.36 3.83 2.87 3.12
EV/Sales
4.11 3.33 2.71 2.94
EV/EBITDA
29.56 24.09 18.65 19.90
EV/FCF
40.91 35.94 27.90 22.78
Current Ratio
1.41 1.35 1.36 1.29
Net Debt/EBITDA
0.00 12.97 13.21 (47.87)
Debt/Equity
0.76 0.92 0.90 0.67
Earnings Yield
0.35% (2.13%) (2.17%) (1.48%)
Free Cash Flow Yield
2.83% 3.40% 4.63% 5.24%
Free Cash Flow per Share
4.34 3.09 (0.30) 1.18
Book value per Share
67.61 59.27 60.19 63.96
Free Cash Flow
207.28 148.62 (14.83) 58.57
EV/EBIT
102.83 147.77 155.10 469.42
Other line items

Show all line items

Columns are period end dates · fundamentals updated 5 Nov 2026